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Abstract
RNAi gene therapies for HIV-1 will likely need to employ multiple shRNAs to counter resistant strains. We evaluated
3 shRNA co-expression methods to determine their suitability for present use; multiple expression vectors, multiple
expression cassettes and single transcripts comprised of several dsRNA units (aka domains) with each being
designed to a different target. Though the multiple vector strategy was effective with 2 shRNAs, the increasing
number of vectors required is a major shortcoming. With single transcript configurations we only saw adequate
activity from 1 of 10 variants tested, the variants being comprised of 2 - 3 different target domains. Whilst single
transcript configurations have the most advantages on paper, these configurations can not yet be rapidly and
reliably re-configured for new targets. However, our multiple cassette combinations of 2, 3 and 4 (29 bp) shRNAs
were all successful, with suitable activity maintained in all positions and net activities comparable to that of the
corresponding single shRNAs. We conclude that the multiple cassette strategy is the most suitably developed for
present use as it is easy to design, assemble, is directly compatible with pre-existing shRNA and can be easily
expanded.
Introduction
The recently discovered RNA interference (RNAi) path-
way is a post-transcriptional gene silencing and regula-
tion mechanism with potential application in the field of
gene therapy. In mammalian cells RNAi begins with a
double-stranded RNA inducer that is progressively pro-
cessed from its termini by RNase III type endonucleases,
firstly Drosha in the nucleus followed by Dicer in the
cytoplasm, to yield a short interfering RNA (siRNA)
duplex of ~ 22 bp [1,2]. The duplex is unwound and
loaded into the RNA induced silencing complex (RISC)
in a process that favors one of the two strands (the guide
strand) based on a difference in thermodynamic stability
at the ends of the duplex [3]. The most common natural
substrates for mammalian RNAi are microRNA, short
hairpin-like RNA transcripts implicated in regulating
gene expression activity [1,2]. The RNAi pathway can be
artificially engaged at any point in the process, typically
either through delivering synthetic siRNAs to the RISC
[4,5] or by expressing short hairpin RNAs (shRNA or
hairpins) to be processed by Dicer and possibly Drosha
[6,7].
shRNAs are well suited for use in current gene therapy
plans. shRNA consists of a short single-stranded RNA
transcript that folds into a ‘hairpin’ configuration by virtue
of self-complementary regions separated by a short ‘loop’
sequence. Whilst hairpins can be expressed from either
polymerase (pol) III or more recently pol II promoters, it
is the U6 and H1 pol III promoters that have been most
extensively employed owing in part to their relatively well-
defined transcription start and end points [6,7]. Impor-
tantly, pol III based hairpin expression cassettes have been
incorporated into viral vectors which have been stably
integrated both in culture and whole animals with effective
silencing maintained over time [8-10]. The potency of
individual shRNA directed to HIV has been extensively
demonstrated [11-13], however, several studies have also
s h o w ns i n g l es h R N Ac a nb er a p i d l yo v e r c o m eb yt h e
emergence of escape mutants [14-17]. Modeling shows
that perhaps as few as 4 shRNAs used in combination may
be sufficient to prevent the emergence of escape mutants
[18-22]. This idea is supported by several wet studies
showing that in laboratory conditions HIV-1 escape can
be delayed by using more than one shRNA [11,23-26].
In a clever variation on this idea, some have designed
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routes, though when tested it was found that the virus still
evolved around these [27,28]. There is now clearly a need
for an evaluation of multiple shRNA expression strategies
to identify those that can be readily integrated into current
anti-HIV gene therapy research programs.
One method for expressing multiple shRNAs is to use
separate expression vectors encoding individual shRNA.
Multiple shRNAs have been used successfully against
cellular, viral and exogenous gene targets by the use of
either multiple plasmid [29], retrovirus [30] or lentivirus
vectors [9]. Multiple shRNAs can also be combined into
a single expression vector via several self-contained
expression cassettes (e.g. 1 cassette = promoter, shRNA
and terminator), of which there are now many examples
[11,31-34]. Alternatively, multiple shRNA domains can
be combined in a single transcript, of which there are
two base configurations; distinct hairpin domains joined
3’ to 5’ in what we call a ‘cluster’ (CL) configuration,
and a ‘head-to-tail’ (HT) configuration in which all the
sense stem regions are joined first, followed by a single
loop and then all the anti-sense regions [17,35-39]. This
second configuration appears as a long hairpin which,
depending on the design, may be punctuated by
unpaired spacer regions between the hairpin domains.
Single transcript strategies are the most compact, and in
this respect the most desirable means of co-expressing
multiple shRNAs for gene therapy, but with few exam-
ples and no design guidelines yet reported, its general
ease-of-use is unclear.
The aim of this study was to evaluate the 3 different
shRNA co-expression methods to determine their suit-
ability for present use in gene therapy schemes, with a
key focus on ease of construction, applicability to new
sequences, and the retention of suppressive activity in
the component shRNAs. We assembled combinations of
2 to 4 shRNAs using 3 different strategies: one using
multiple expression vectors, one using multiple hairpin
expression cassettes and the other based on a single
transcript comprised of different hairpin domains. While
we were able to achieve successful suppression with
each strategy, we concluded that the multiple cassette
strategy is currently most useful due to ease of design,
assembly, and its immediate compatibility with pre-
existing shRNA already selected for high activity.
Results
Co-expression using multiple vectors
The effects of co-expressing hairpins of different
sequence were first examined in its simplest form; using
two hairpins, each expressed from a separate plasmid
vector (pS) derived from pSilencer 3.0-H1 (Ambion).
In this circumstance the suppressive activities of each
hairpin were measured when separately expressed, and
then again when co-expressed. All hairpins in this study
were expressed from the human H1 polymerase III pro-
moter. This experiment employed two 29 bp shRNAs
against the HIV-1 genes encoding for Tat and Vif: Tat
56-29 (T)a n dV i f8 8 - 2 9( V) (variant NL4-3, accession
#AF324493) (Table 1). Suppressive activity was mea-
sured by flow cytometry as a reduction in fluorescence
of an appropriate reporter after transfection and transi-
ent expression of both hairpin(s) and reporter(s) in
HEK293a cells. In this and all subsequent experiments
the activity of each shRNA vector was measured relative
to the activity of the appropriate control vector contain-
ing an equivalent number of ‘empty’ (e) expression cas-
settes (i.e. consisting of a promoter(s) plus terminator
but expressing no hairpin(s)).
Either the two hairpin vectors, or each hairpin vector
and the equivalent control vector were co-transfected at
different ratios (Figure 1). The total amount of DNA
delivered for each transfection was kept constant and the
shRNA expression vector was always present at a level
such that the RNAi process would presumably be satu-
rated so that the effects of competition, if any, would be
evident [40]. As each hairpin was directed to a different
target the suppressive activity was measured using two
unique reporters (GFPsTat and AsRed1sVif), which
could be detected both simultaneously and indepen-
dently. The specific activity of each hairpin vector was
unaffected in the presence of empty expression vector at
all ratios. However, the specific activity of each hairpin
when co-expressed was progressively reduced at ratios
that increasingly favored the competing hairpin. We sur-
mise that reduction in specific activity was not due to a
second vector (or promoter), but rather from inter-hair-
pin competition for access to the RNAi machinery. In
summary, co-expressed hairpins delivered via separate
vectors can function simultaneously, but do so at reduced
levels due to competitive access for the RNAi machinery.
Co-expression using multiple-cassette vectors:
establishing positional effects
An alternative strategy to overcome the obvious limita-
tions of using multiple vectors to co-express hairpins (e.g.
issues of vector multiplicity) was to incorporate multiple
hairpin expression cassettes within a single vector. How-
ever, to address concerns of potential promoter or tran-
scriptional interference [41] it was important to first
determine if each individual cassette position in a multiple
cassette vector was capable of expressing a hairpin that
functioned with equivalent suppressive activity. At this
point we switched to using a pLenti6 derived vector back-
bone (pL) (Invitrogen) so that we could later test our con-
structs in stably transduced scenarios. We assembled a
series of 1, 2, 3 and 4 cassette vectors containing only a
single hairpin (T) expression cassette per vector, which
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positions consisted of ‘empty’ expression cassettes, e.g. the
3 cassette vectors included 3.1: T+e+e,3 . 2 :e+T+e,a n d
3.3: e+e+T. There was ~ 130 bp of spacer sequence
between each cassette, as measured from the terminator
of one cassette (n) to the promoter of the next down-
stream cassette (n+1). Control vectors were also created
that were of corresponding sizes and were composed of an
equivalent number of all empty expression cassettes (2 to
4). Suppressive activity was first measured by flow cytome-
try as a reduction in fluorescence after transfection and
transient expression from both hairpin and reporter vec-
tors (Figure 2a). There was no apparent reduction in activ-
ity from any cassette position, from either the 2, 3 or 4
cassette vectors, with each cassette position retaining full
hairpin activity equivalent to the single position, single
hairpin cassette vector.
Co-expression using multiple-cassette vectors:
multiplication of a single hairpin
pLenti6 based vectors with 2, 3, and 4 cassettes were con-
structed with an identical hairpin (T) expression cassette
placed in all positions to investigate whether increasing
the cassette number could increase the suppressive
activity (e.g. 2×: T+T,3 × :T+T +T,a n d4 × :T+T+T+T).
Suppressive activity was measured across a range of vec-
tor amounts (from 400 - 0 ng) so that the effects of
increasing cassette number could be investigated during
both RNAi-saturating and sub-saturating conditions
(Figure 2b). The total amount of DNA delivered for each
transfection was kept constant by supplementing each
reaction with the appropriate amount of corresponding
control vector whilst keeping the amount of reporter vec-
tor constant. There were no differences in the suppres-
sive activities from 400 ~ 100 ng of each vector delivered,
which supported the hypothesis that the RNAi process
was saturated across this range. However, at 50 - 10 ng of
vector(s) there were statistically significant improvements
in suppressive activity (*) with increasing cassette num-
bers (P < 0.05, comparing the single cassette vector to
the 2, 3, and 4 cassette vectors). The trend did not extend
below this concentration range, as effective suppressive
activity was lost and accordingly any meaningful differ-
ence between the different numbers of cassettes.
We further examined whether multiplying an identical
expression cassette would be beneficial in stably trans-
duced cell lines. Infectious virus was generated from each
o ft h e1 ,2 ,3a n d4( T) cassette vectors, along with the
Table 1 shRNA sequences
r
a Target In.
b Stem (sense) Loop Te.
b Len.
T Tat 56-29 G AAACUGCUUGUACCAAUUGCUAUUGUAAA ACTCGAGA G 70
V Vif 88-29 G UAUAUUUCAAGGAAAGCUAAGGACUGGUU UCTCGAGU - 69
R Vpr 72-29 - GGAACUUAAGAGUGAAGCUGUUAGACAUU ACTCGAGA - 68
U Vpu 158-29 - GCAAUGAGAGUGAAGGAGAAGUAUCAGCA ACTCGAGA - 68
O’ Off #1-29 - AAGACAGUCCAACACACGCCACCUGUCUC UCTCGAGU - 68
O” Off #2-29 - AACAGUCUGUCAAAGGUGACCCCUGUCUC UCTCGAGU - 68
T
19 Tat 59-19 - CUGCUUGUACCAAUUGCUA UUCUCGAGA - 50
V
19 Vif 98-19 - GGAAAGCUAAGGACUGGUU UCTCGAGU - 48
a: shRNA abbreviation.
b: In. (Initiating)/Te. (Terminating): Extra nucleotides included 5’(the first nt. transcribed) and 3’ (the last nt. transcribed prior to 1 or more U termination remnants)
in only some sequences (those which were also a part of an overlapping study).
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Figure 1 Activities of different shRNAs from different vectors.( a) The first two test hairpins, Tat 56-29 (T) and Vif 88-29 (V), were expressed
from separate plasmid vectors (pS) via the H1 polymerase III promoter. HEK293a cells were transfected with 800 ng of the pSilencer-based (pS)
T vector (+ empty) (b), the V vector (+ empty) (c), or the T and V vectors together (d) at mass ratios of 1:7 to 7:1, plus 100 ng each of both
target-specific reporter vectors GFPsTat (T.r) and AsRed1sVif (V.r-red). There were 9 data points plotted for each curve, though for clarity open
circles are only shown on every 2nd one. The data shown is representative of several replicated experiments (repeated twice, i.e. n = 2).
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Page 3 of 11empty control vectors, and another corresponding series
of off-target shRNA cassette vectors (using an unmatched,
off-target, 29 bp hairpin (O’)i n1 ,2 ,3 ,a n d4c a s s e t t ec o m -
binations). Interestingly, when preparing virus, we saw a
steady decrease in titre that correlated with increasing cas-
sette number for both hairpin containing and empty
expression cassette vectors (Figure 2c). We infected (trans-
duced) HEK293a cells, selected for stable integrants, and
measured suppressive activity by transfecting and transi-
ently expressing the relevant reporter vectors into each
cell line (Figure 2d). Analysis of the off-target hairpin con-
trols showed no deleterious impact on fluorescence
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Figure 2 Activities of individually expressed shRNAs from the same vector.( a) 400 ng each of a series of 1, 2, 3 and 4 cassette (ca) pLenti6
(pL) based vectors with only a single hairpin per vector (surrounded by ‘empty’ expression cassettes) were assayed with 300 ng each of T.r
(target-specific) and V.r-red (control) (n = 3). (b) 0 - 400 ng each of a series of 1×, 2×, 3× and 4× cassette pL vectors with all cassettes containing
a T shRNA were assayed with 300 ng each of T.r and V.r-red. Total DNA delivered was kept constant at 1 μg by supplementing samples (as
required) with the corresponding empty control vector. Statistically significant improvements in suppressive activity (*; P < 0.05) at 10 and 50 ng
are shown at a finer scale (comparing the single cassette vector to the 2, 3, and 4 cassette vectors). (n = 3) (c) Viral titres of the Infectious virus
produced from the 1×, 2×, 3× and 4× all T cassettes vectors, and the corresponding off-target (O’) and empty (”e“) series (n = 1). (d) Stably
integrated HEK293a cell lines for the 1× - 4× T, O’ and e cassette vectors were assayed with 300 ng each of T.r and V.r-red, plus 400 ng of the
appropriately matched 1 - 4 e cassette vector (to maintain a constant transfection amount of 1 μg) (n = 1). (e) 400 ng each of single shRNA
vectors and a series of 1, 2, 3 and 4 cassette vectors made from 4 different shRNAs (T, V, R, and U) were separately assayed with 300 ng each of
the 4 corresponding GFP fusion reporters T.r, GFPsVif (V.r), GFPsVpr (R.r) and GFPsVpu (U.r) plus 300 ng of an AsRed1sNef control (N.r-red).
(*) There was a statistically significant reduction in the individual suppressive activities of each hairpin relative to their single counterparts (P <
0.01) (n = 1). (f) Net suppressive activities of the same vectors were measured using a HIV-1 production assay by transfecting HEK293a cells with
110 - 130 ng of shRNA vector with 800 ng of pNL4-3 reporter and measuring the impact on p24 production (n = 2).
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hairpins. However, the suppression levels from the Tat-
specific shRNA cell lines were reduced by ~ 30 - 40% rela-
tive to the maximum levels observed during transient
expression (cf. Figure 2b), which was not unexpected and
most likely due to low-copy number integration with a
corresponding reduction in shRNA expression [8,18,42].
In this stable expression system there were no statistically
significant differences in suppressive activity between the
2, 3 and 4 cassette cell lines.
Co-expression using multiple-cassette vectors:
diversifying hairpin targets
The multiple cassette strategy was further investigated
by combining four different shRNA in a single vector
using the same pL base vectors and cassette configura-
tions as before. In addition to Tat 56-29 and Vif 88-29,
two further (HIV-1) 29 bp shRNA were used: Vpr 72-29
(R)a n dV p u1 5 8 - 2 9( U). Each shRNA was placed in
both single cassette vectors and combination vectors of
2( T+V), 3 (T+V+R)a n d4( T+V+R +U) cassettes. All
vectors were assayed in turn with each of the relevant
reporter vectors enabling the specific activity of each
shRNA to be measured independently (Figure 2e). Each
individual hairpin exhibited potent and specific activity
for its matched assay vector(s). There was, however, a
progressive and statistically significant reduction in the
individual suppressive activity of each hairpin when
expressed in combinations of increasing number, relative
to the corresponding individual shRNA (P < 0.01), the
exception being Vpu 158-29, which appeared unaffected.
The activity of each vector was further examined using
HIV-1 as the target and p24 production (a capsid pro-
tein) as the readout (Figure 2f). Whilst each hairpin was
of a different sequence, their activities were now mea-
sured via a common endpoint (p24 production) and
thus each could be considered as being directed towards
a “common or shared target”. The net suppressive activ-
ity of each multiple hairpin vector was similar to the
corresponding individual hairpin vectors (all within 5%
of each other). We concluded that whilst hairpins com-
pete with each other for access to RNAi machinery, a
net suppressive activity can be maintained from multiple
simultaneously acting shRNAs.
Co-expression using single transcript arrays of hairpin
domains
The last co-expression strategy tested was the single
transcript strategy comprised of several shRNA domains
(or technically just dsRNA domains, depending on
design). There are two basic configurations, the ‘cluster’
(CL) configuration and the ‘head-to-tail’ (HT) configura-
tion. Using pSilencer based vectors, we constructed two
cluster arrays of three 29 bp hairpin domains (R_V_T1
and R_V_T8) with either 1 or 8 nt. spacers separating
each domain (Table 2), and tested them with our fluor-
escent reporters (Figure 3a). Despite reported success
from others [43,44], we only saw good activity in the
first domain, with poor activity in the remaining two.
Following this we created a head-to-tail configuration
comprised of two 29 bp hairpin domains (V-T) separated
by an 8 nt. spacer. Suppressive activity was measured for
both domains simultaneously by using dual reporters
(GFPsTat and AsRed1sVif), which showed that each
domain was simultaneously active (Figure 3b). We also
show that this result was target-specific, since a second
control molecule similarly constructed from two 29 bp off-
target hairpin domains (O’-O”)s h o w e dn os u p p r e s s i v e
activity (Figure 3c). We further transferred the V-T head-
to-tail configuration into a our pLenti6 based plasmid and
assayed it using HIV-1 (i.e. a shared target) (Figure 3d).
The net suppressive activity was comparable to the activ-
ities of the corresponding individual shRNAs and the com-
bined activities of both individual shRNAs when delivered
via the equivalent multiple cassette strategy. Encouraged by
this finding, we assembled and tested several more head-
to-tail configurations, comprised of the same domains but
in different order (T-V), different domains (U-R and R-U),
more domains (R-V-T and T-V-R), no spacers (V-To), and
shorter 19 bp domains (V
19-T
19). However, in no case did
we achieve a similarly successful outcome to our original
V-T molecule (Figure 3e-h). While some domains were
active, others were not, and no configuration retained com-
parable activity to the corresponding component shRNAs
for all domains. We conclude that while two hairpins com-
bined in a head-to-tail configuration can be successful, reli-
ably obtaining an active molecule requires a more detailed
design (than simply connecting pre-existing hairpins) that
will come from a better understanding of how these config-
urations are processed.
Discussion
In this study we tested 3 different strategies for the
simultaneous expression of multiple hairpins and showed
that all could be effective. But, the multiple vector strat-
e g yi sl i k e l yt ob eo fl i m i t e du s ei ng e n et h e r a p ys i n c ei t
requires a unique vector per shRNA, with potential issues
in ensuring that each cell receives all vectors (without
which may facilitate the emergence of resistant strains).
The single transcript strategy was effective in one
instance, but since similar success was not reproduced
with different domains (or configurations), it is also of
limited use in its present form. However, the multiple
expression cassette strategy was used successfully with
up to 4 shRNAs, and was easy to assemble and expand
with pre-selected shRNAs.
When hairpins were co-expressed at levels that satu-
rated the RNAi process we found that the individual
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reduced with increasing numbers of hairpins co-
expressed. This was equally applicable for all three hair-
pin co-expression strategies; multiple vectors, multiple
cassettes, and multiple domains. Hairpin competition
was evident in all cases except one, where the activity of
the Vpu 158-29 hairpin was little affected when transi-
ently expressed with 3 other hairpins from a 4 cassette
vector. Although the reasons for this are unknown to us,
we note that this hairpin was very active and so it may be
that even as it competed with 3 other shRNA its suppres-
sive impact was unaffected. Overall, we surmise that hair-
pins interact competitively for access to the RNAi
machinery. Whilst this conclusion is supported by some
[45-47], it is worth noting that there are also conflicting
conclusions, where others report no evidence of shRNA/
siRNA competition [29,30,48,49]. The reason for this dis-
parity may relate to differences in experimental design
such as expression levels and observations under sub-
saturating conditions. It should also be noted that issues
of shRNA competition in mammalian cells encompass
endogenous RNAi substrates as well, e.g. microRNA.
Expression levels in a clinical setting may need to be
finely tuned to attain sufficient activity, with minimal
impact [2,50-53]. Another idea for removing competition
may be to employ multiple agents of different modalities
( e . g .R N A i ,a p t a m e r sa n dr i b o z y m e s )s ot h a tn os i n g l e
pathway is overwhelmed [54,55].
When each hairpin of different sequence was directed to
a common target (i.e. the complete HIV-1 sequence rather
than individual gene-fusions), we saw that the net suppres-
sive activity was approximately equivalent to the average
activity of the component hairpins. This suggests that hair-
pin diversity may be increased whilst maintaining overall
suppressive activity. This could potentially be exploited for
countering the emergence of viral escape mutants in-line
with other studies [27] though it requires further work for
verification. Moreover, we did not test the effect on net
activity of using one or more hairpins which was poor, or
completely inactive (as all our hairpins here were classed
as highly active). Such a situation could conceivably arise
in a clinical setting due to a virus developing a mutation in
one of the target sites. We speculate that the net suppres-
sive activity would be reduced, though our mathematical
modeling of various infection scenarios indicates that
some loss of shRNA efficacy can be tolerated without
impacting on treatment success [21,22].
Our data shows that up to 4 repeats of the same shRNA
can increase the net suppressive activity when transiently
expressed at levels below that which results in maximal
Table 2 Multiple domain, single transcript sequences
Comb. Sequence
a Len.
R_V_T1 GGAACUUAAGAGUGAAGCUGUUAGACAUUACUCGAGAAAUGUCUAACAGCUUCACUCUUAAGUUCCGUAUAUUUCAAGGAAAG
CUAAGGACUGGUUACUCGAGAAACCAGUCCUUAGCUUUCCUUGAAAUAUAGAAACUGCUUGUACCAAUUGCUAUUGUAAA
ACUCGAGAUUUACAAUAGCAAUUGGUACAAGCAGUUUGUx
204
R_V_T8 GGAACUUAAGAGUGAAGCUGUUAGACAUUACUCGAGAAAUGUCUAACAGCUUCACUCUUAAGUUCCGCUGCAGGUAUA
UUUCAAGGAAAGCUAAGGACUGGUUACUCGAGAAACCAGUCCUUAGCUUUCCUUGAAAUAUAGGACGUCGAAACUGCUUG
UACCAAUUGCUAUUGUAAAACUCGAGAUUUACAAUAGCAAUUGGUACAAGCAGUUUGUx
218
V-T GUAUAUUUCAAGGAAAGCUAAGGACUGGUUGCUGCAGGAAACUGCUUGUACCAAUUGCUAUUGUAAAACUCGAGA
UUUACAAUAGCAAUUGGUACAAGCAGUUUGGACGUCGAACCAGUCCUUAGCUUUCCUUGAAAUAUAUx
144
O’-O” AAGACAGUCCAACACACGCCACCUGUCUCGCUGCAGGAACAGUCUGUCAAA
GGUGACCCCUGUCUCACUCGAGAGAGACAGGGGUCACCUUUGACAGACUGUUGGACGUCGGAGACAGGUGGCGUGU
GUUGGACUGUCUUGUx
144
T-V GAAACUGCUUGUACCAAUUGCUAUUGUAAAGCUGCAGGUAUAUUUCAAGGAAAGCUAAGGACUGGUUACUCGAGA
AACCAGUCCUUAGCUUUCCUUGAAAUAUAGGACGUCGUUUACAAUAGCAAUUGGUACAAGCAGUUUGUx
145
U-R GGCAAUGAGAGUGAAGGAGAAGUAUCAGCAGCUGCAGGGGAACUUAAGAGUGAAGCUGUUAGACAUU
ACUCGAGAAAUGUCUAACAGCUUCACUCUUAAGUUCCGGACGUCGUGCUGAUACUUCUCCUUCACUCUCAUUGCGUx
145
R-U GGGAACUUAAGAGUGAAGCUGUUAGACAUUGCUGCAGGGCAAUGAGAGUGAAGGAG
AAGUAUCAGCAACUCGAGAUGCUGAUACUUCUCCUUCACUCUCAUUGCGGACGUCGAAUGUCUAACAGCUUCACU
CUUAAGUUCCGUx
145
R-V-T GGAACUUAAGAGUGAAGCUGUUAGACAUUGCUGCAGGUAUAUUUCAAGGAAAGCUAAGGACUGGUUGCUGCAGG
AAACUGCUUGUACCAAUUGCUAUUGUAAAACUCGAGAUUUACAAUAGCAAUUGGUACAAGCAGUUUGGACGUCG
AACCAGUCCUUAGCUUUCCUUGAAAUAUAGGACGUCGAAUGUCUAACAGCUUCACUCUUAAGUUCCUx
217
T-V-R AAACUGCUUGUACCAAUUGCUAUUGUAAAGCUGCAGGUAUAUUUCAAGGAAAGCUAAGGACUGGUUGCUGCAGG
GGAACUUAAGAGUGAAGCUGUUAGACAUUACUCGAGAAAUGUCUAACAGCUUCACUCUUAAGUUCCGGACGUCG
AACCAGUCCUUAGCUUUCCUUGAAAUAUAGGACGUCGUUUACAAUAGCAAUUGGUACAAGCAGUUUUx
217
V-T0 GUAUAUUUCAAGGAAAGCUAAGGACUGGUUAAACUGCUUGUACCAAUUGCUAUUGUAAAACUCGAGA
UUUACAAUAGCAAUUGGUACAAGCAGUUUAACCAGUCCUUAGCUUUCCUUGAAAUAUAUx
128
V
19
-T
19 GGGAAAGCUAAGGACUGGUUGCUGCAGGCUGCUUGUACCAAUUGCUAUACUCGAGAAUAGCAAUUGGUAC
AAGCAGGGACGUCGAACCAGUCCUUAGCUUUCCUx
106
a: sequences external to the target-matched dsRNA domains are shown in bold (e.g. loops, spacers, Ux termination remnants).
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Page 6 of 11suppressive activity. Interestingly, the same effect was not
seen in the corresponding stably transduced cell lines. The
reasons for this are unclear, but could result from promo-
ter interference [41], or transcriptional silencing [56].
Other studies have shown that promoter interference is
not necessarily a barrier to multiple shRNA cassette strate-
gies [31,32,54]. One study has shown that up to 6 identical
expression cassettes could increase total expression and
suppressive activity during both transient and stable
expression, though in this case more than six cassettes was
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Page 7 of 11deleterious in stable expression as it decreased the net
suppressive activity [32]. Repeat-mediated cassette deletion
is also a concern, as we and others have since shown that
it commonly occurs during infection [21,51], possibly via
reverse transcriptase slipping on its template [57], though
again, our modeling suggests that the practical impact of
this in a gene therapy setting may be low [21]. Finally, the
reduction in titre that we observed, whilst inconsequential
here, has also been noted by others [42,58-60] and is an
issue that may have to be addressed prior to scaled-up
manufacturing.
Our attempts to generate a cluster of 3 shRNA
domains in a single transcript with activity retained
equally in each domain were unsuccessful. However,
due to the highly structured templates, we were unable
to confirm the sequence of these templates with auto-
mated sequencing procedures. Thus we cannot rule out
the possibility of single nucleotide errors in these config-
urations. This is another issue that needs to be over-
come, though Liu et. al. have reported success by
incorporating several G:U wobbles [61]. Head-to-tail
configurations can be sequenced though (using a modi-
fied protocol [62]), and in this respect may be a more
attractive choice. However, since these are akin to ‘long’
hairpins, they in turn may induce non-specific dsRNA-
response pathways such as protein kinase R (PKR) or
interferon (IFN) [63,64], though recent work suggests
otherwise [61]. Even though our designs incorporated
spacers (of 1 or 8 nt.) to keep all regions of paired dou-
ble-stranded RNA less than 30 bp (the minimal length
traditionally thought to activate non-specific pathways),
there are reports that some structures outside of this
traditional view (e.g. < 30 bp) may also stimulate these
responses [65-68]. At this point though, the principle
limitation of these configurations is in not knowing how
they are processed, and consequently how they should
be designed to reliably retain activity in all domains.
Based on our understanding of single shRNA proces-
sing, where a single nt. shift in the start of the shRNA
stem can significantly alter activity, we speculate that
the processed products from our multiple domain con-
structs are simply different from the those liberated
from the ‘corresponding’ single shRNAs. Liu et. al.a n d
others are making inroads in this area [61,69], which
will be well complemented by future deep-sequencing
type studies. It is interesting to note that others who
have also looked at similar structures have been simi-
larly unable to produce effective silencing from more
than 3 domains [61]. As a workaround one group has
stacked several 2-domain structures, which could then
be further used in combination with a multiple cassette
type arrangement to increase targeting capacity [39].
In summary, we found that while all 3 co-expression
strategies tested were effective, the multiple cassette
strategy is a most useful method for immediate use in
gene therapy. This is because it was easy to design, assem-
ble, and is directly compatible with pre-existing shRNA
already selected for high activity. It is worth noting that a
similar study was published during the preparation of this
manuscript, with similar conclusions, thus strengthening
the validity of our findings [70]. Furthermore, we have
since applied the multiple cassette strategy in several addi-
tional studies, including the development of a repeating
modular cloning method (tested with up to 11 shRNAs),
the assembly of combinations of up to 7 shRNAs to target
entire subtypes of HIV-1, and a large-scale study around
repeat-mediated deletion of 1 or more cassettes [21,71].
Methods
shRNA design and vector construction
Each shRNA was designed so that the sense or upper
strand of the shRNA stem was homologous to the target
(designed to give rise to the siRNA passenger strand)
and the anti-sense or lower strand of the shRNA stem
was complementary to the target (designed to give rise
to the siRNA guide strand) (Table 1). Sense and anti-
sense strands were connected by an 8 or 9 nt loop and
all hairpins were expressed from a human H1 polymer-
ase III (pol III) promoter with transcription presumably
terminating at a run of 4 or more ‘T’ residues in the
included termination signal (TTTTTTGGA). Each
shRNA insert was constructed using either annealed
complementary oligonucleotides (oligos) or primer
extension [62] to create a synthetic DNA insert that was
cloned into a pSilencer 3.0-H1 derived vector (Ambion).
The pSilencer derivative was generated by replacing the
bla gene (ampicillin
r) for the neo gene (kanamycin
r
/G418
r). Single cassette pLenti6 based vectors were cre-
ated by sub-cloning entire shRNA expression cassettes
from the pSilencer based vectors into a derivative of
pLenti6/V5-D-TOPO (Invitrogen). The pLenti6 deriva-
tive was generated by exchanging the CMV promoter,
V5 epitope and SV40 terminator region for a multiple
clone site (MCS) to facilitate the unique insertion of 1
to 4 self-contained (i.e. consisting of promoter, hairpin
and terminator) shRNA expression cassettes. Multiple
cassette pLenti6 based vectors were created by PCR
amplification of the desired cassette(s) from the corre-
sponding pSilencer based vector(s), which were then
progressively inserted into the appropriate pLenti6
based vector downstream of any previous cassettes with
a gap of ~ 130 bp separating each cassette. pSilencer
based vectors were propagated in GT116 E. coli cells
(a cell line specifically developed for the replication of
hairpin containing vectors, Invivogen) and pLenti6 based
vectors were propagated in Stbl3 E. coli cells (manufac-
turer recommended cell line, Invitrogen). DNA was
extracted (Hi-speed Maxi-prep Kit, Qiagen), quantitated
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Page 8 of 11in triplicate and was sequence confirmed either by stan-
dard protocols or a modified protocol where required to
enable automated sequencing of hairpin expression vec-
tors possessing reaction-inhibiting secondary structure
[62] (excluding the multiple hairpin ‘cluster’ configura-
tions as indicated in the text).
Reporter vector construction
The fluorescent protein-target fusion reporter vectors,
were constructed using EGFP (from pd4-d4EGFP-N1,
BD Biosciences), AsRed1 (from pAsRed1-C1, BD Bios-
ciences) or AmCyan (from pAmCyan-C1, BD Bios-
ciences) and HIV-1 sequences (variant NL4-3, accession
#AF324493). Each vector was designed to produce a sin-
gle mRNA transcript comprising the fluorescent protein
fused to a downstream HIV-1 gene sequence but sepa-
rated by multiple stop codons to ensure that only the
first domain would be translated (the fluorescent pro-
tein). The sizes of reporter vectors deviated by no more
than 10%. The reporters used here included: GFPsTat
(T.r) and AsRed1sVif (V.r-red), GFPsVif (V.r), GFPsVpr
(R.r) and GFPsVpu (U.r), and AsRed1sNef (N.r-red).
Fluorescence based shRNA activity assay
Human Embryonic Kidney cells (HEK293a, sourced
from the American Type Culture Collection) were
seeded at a density of 4 - 5 × 10
5 cells/well in 6 well
plates in 2 ml of Dulbecco’s modified eagle medium
plus 10% fetal bovine serum (DMEM-10). Cells were
transfected 1 day later using 1 μgo ft o t a lD N A( c o m -
prised of different amounts of shRNA and/or 1 or more
reporter vectors as indicated in each figure) with 4 μlo f
Lipofectamine 2000 (Invitrogen) in OptiMEM (Invitro-
gen) to a total volume of 100 μl/well. Cells were ana-
lyzed by flow cytometry 2 days later (using either a
FACsort or FACsCalibur instr u m e n t ,B DB i o s c i e n c e ) .
The suppressive activity of each shRNA was measured
as a change in fluorescence of the reporter(s) (FL1 for
‘green’ proteins and FL2 for ‘red’ proteins). The Fluores-
cence Index (FI) of cells in each channel was calculated
by multiplying the geo mean of fluorescence by the per-
centage of cells that were fluorescent (only those cells
gated above background). The FI was expressed as a
percentage of the FI of cells transfected only with the
corresponding empty expression control vector that
expresses no hairpin. Target-specific shRNA activities
were normalized to account for non-specific effects
measured using an additional ‘green’ or ‘red’ off-target
reporter to which the shRNA bore no homology, except
for cases where the simultaneous activities of 2 shRNAs
where measured using a ‘green’ reporter for one shRNA,
and a ‘red’ reporter for the other shRNA. Most assays
included a 29 bp off-target control shRNA (O’), which
displayed no meaningful suppressive activity against any
reporter, and thus was omitted from the graphs for
clarity.
Lentivirus production and infection
293FT cells (Invitrogen) were seeded at a density of 5 ×
10
6 cells/plate (100 mm plates; 10 ml DMEM-10) and
were transfected 1 day later using 12 μgo ft o t a lD N A
(comprised of 3 μg pLenti6 based hairpin vector and 9 μg
packaging vectors, Invitrogen) with 36 μl of Lipofectamine
2000 in OptiMEM to a total volume of 8 ml/plate. Virus-
containing medium (VCM) was harvested at 2 - 3 days
post-transfection, cold spun at 3000 rpm for 15 min. and
stored at -80°C. Viral titres were calculated using
HEK293a cells seeded at 1 × 10
5 cells/well (6 well plates;
2 ml DMEM-10) which were infected with serial dilutions
of VCMs ranging from 10
-1 to 10
-6 supplemented with
6 μg/ml of polybrene (hexadimethrine bromide, Sigma).
Selective medium (DMEM-10 plus 10 μg/ml Blasticidin,
Invitrogen) was applied to infected cells 2 days later and
maintained for 10 - 14 days prior to Giemsa staining
(Merck) and quantification of colony numbers, with titres
calculated as infectious viral particles (IVF)/ml of VCM.
Stably transduced cell lines were generated using
HEK293a cells seeded at a density of 4 × 10
5 cells/plate
(6 well plates; 2 ml DMEM-10) which were infected 1 day
later with 2 ml of VCM with an average MOI of ~ 0.4.
Selective medium (DMEM-10 plus 10 μg/ml Blasticidin)
was applied to infected cells 4 days later and maintained
for at least 14 days.
HIV-1 production assay
HEK293a cells were seeded at a density of 2 × 10
5 cells/
well (12 well plates; 1 ml of DMEM-10). Cells were trans-
fected 1 day later using 110 - 130 ng of hairpin expres-
sion vector (at equimolar amounts across transfections)
and 800 ng (3× molar amount of expression vector) of
pNL4-3 reporter vector (expressing the 4-3 strain of
HIV-1) with Lipofectamine 2000 at a ratio of 1 : 4 (μg
DNA: μl Lipofectamine) in OptiMEM to a total volume
of 200 μl/well. Medium was replaced with an equal
volume 1 day post-transfection and the cells were har-
vested a further 1 day later by centrifugation at 400 g for
10 min. at room temperature. Samples were stored at
-20°C until assayed for p24 levels (a capsid protein
required for HIV-1 virion production) via Enzyme-
Linked Immunosorbent Assay (ELISA) using the
INNOTEST HIV antigen mAb kit (Innogenetics). The
suppressive activity of each shRNA was measured as a
reduction in, and expressed as percentage of, p24 pro-
duction (measured as pg/ml) relative to p24 production
from cells transfected with the corresponding empty
expression control vector.
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Each sample was analyzed in triplicate with 95% confi-
dence intervals (CI) calculated using Microsoft Excel X.
P values were determined by analysis of variance
(ANOVA, with a Bonferroni’s multiple test comparison)
using Prism 4.0a.
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